FY2024 EPS Estimates for CeriBell Cut by William Blair

CeriBell (NASDAQ:CBLL) – Investment analysts at William Blair dropped their FY2024 earnings per share estimates for CeriBell in a report issued on Wednesday, November 13th. William Blair analyst M. Andrew now anticipates that the company will post earnings of ($3.07) per share for the year, down from their prior estimate of ($0.99). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CeriBell’s current full-year earnings is ($2.11) per share. William Blair also issued estimates for CeriBell’s Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.01) EPS.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The business had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million.

CBLL has been the subject of a number of other research reports. JPMorgan Chase & Co. assumed coverage on CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target for the company. Canaccord Genuity Group lifted their target price on CeriBell from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen began coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $31.00 price target on the stock. Canaccord Genuity Group began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Bank of America assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $31.20.

CeriBell Price Performance

Shares of CBLL opened at $25.57 on Monday. CeriBell has a one year low of $23.00 and a one year high of $29.53.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.